Presbyopia: An outstanding and global opportunity for early detection of pre-frailty and frailty states

Almudena Crooke1,2*, Irene Martínez-Alberquilla2,3, David Madrid-Costa2,3 and Javier Ruiz-Alcocer2,3

1Department of Biochemistry and Molecular Biology, Faculty of Optics and Optometry, Universidad Complutense de Madrid, Madrid, Spain, 2Clinical and Experimental Eye Research Group, Faculty of Optics and Optometry, Universidad Complutense de Madrid, Madrid, Spain, 3Department of Optometry and Vision, Faculty of Optics and Optometry, Universidad Complutense de Madrid, Madrid, Spain

KEYWORDS
presbyopia, frailty, age-related eye diseases, tear, pre-frailty

Introduction

According to the World Population Prospects 2022 of the United Nations, the world's population will rise over the next decades (e.g., by 6.3 and 21% from 2022 to 2030 and 2050, respectively) (1). Likewise, the population of older persons is increasing (1). Indeed, the United Nations expects that the share of the global population aged 65 years and above will rise by 6% between 2022 and 2050 (1). Consequently, age-related diseases, including eye ones, are expected to be very prevalent (2–4). For this reason, population aging is a crucial demographic issue with a growing global impact on all socioeconomic areas (4). This fact has provoked different global initiatives like the one declared by the United Nations in 2020, called the Decade of Healthy Aging 2021–2030, whose aim is to promote and maintain the wellbeing of older adults (5). Hence, as the population ages, an increase in those numbers is expected, and by 2050 866 million of 112 cases and 18.5 cases per 1,000 people, respectively (2). Indeed, vision impairment and blindness affect multiple functional domains (physical, cognitive, psychological, social) and overall quality of life and wellbeing (6). Now, 510 million people have impaired vision, and 43.3 million are blind (7). Among these people, older adults present with a moderate/severe vision impairment and blindness prevalence of 112 cases and 18.5 cases per 1,000 people, respectively (7). Age-related eye diseases (e.g., cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy) are the leading global causes of visual impairment and blindness (6, 8). Hence, as the population ages, an increase in those numbers is expected, and by 2050 866 million and 61.0 million people will have moderate/severe vision impairment and be blind, respectively (7). Consequently, this global eye health initiative urges, like healthy aging initiatives, an in-depth understanding of the aging process and its associated diseases for preventing or delaying age-related eye conditions (6, 9).
Age-related eye changes: Presbyopia

The aging process involves a progressive decline of all organ-specific functions, including eye ones. Like the rest of the body, the eye undergoes age-triggered changes that alter its structures, impairing its physiological functions ([10] review eye changes critical for the onset of age-related eye diseases). One of these impaired functions is the accommodation process. This process, which allows focusing on near objects, occurs by the harmonized action of the ciliary muscle and the zonule fibers which hold the lens in place. Aging triggers changes in these structures involved in accommodation, leading to the gradual inability of the eye to focus (11, 12). This physiological event called presbyopia starts to express itself at around 40 years and affects 100% of the population by age 50 (13, 14). The tell-tale symptom of presbyopia is blurred vision while reading, sewing, using a mobile phone, tablet, computer, or doing anything that requires intermediate and near vision (5). Furthermore, presbyopia may present with eyestrain and headaches after reading or doing close-up work (5). Therefore, it negatively impacts the individuals’ quality of life, urging them to seek a solution from an eye specialist (15–17).

Frailty and eye

Frailty is an age-related syndrome that implies changes at all physiological levels, leading to a state of vulnerability, which could facilitate age-related disease onsets (18). A recent systematic review has shown that the overall prevalence of frailty and pre-frailty among individuals aged 50 years and older varies between 12–24% and 46–49%, respectively (19). Likewise, another systematic review has revealed that the incidence of frailty and pre-frailty among older adults is 43.4 and 150.6 new cases per 1,000 person-years, respectively (20).

Several recent studies have identified pre-frailty/frailty signs in middle-aged adults (40–50 years old) (21–23). Even more notable is that this frailty/pre-frailty condition is associated with multimorbidity and mortality in UK older/middle-aged participants of a prospective analysis (22). So, early detection of this condition could allow rapid implantation of measures that prevent or delay these poor health outcomes (22). Unfortunately, its multiple signs and symptoms (often non-specific) and the limited knowledge of its underlying molecular mechanisms (mainly in middle-aged adults) have hindered its early diagnosis (18).

The World Health Organization (WHO) has introduced the concept of intrinsic capacity (IC) (i.e., the combination of all the individual’s physical and mental capacities) as a crucial component of healthy aging (24). It has also provided recommendations and tools to manage IC decline at the community level and primary care level, assuring integrated care for older adults (ICOPE) (25, 26).

According to the WHO ICOPE guidelines, vision is a critical component of IC (26). A simple eye chart permits the measurement of visual capacity, and distance acuity worse than 6/18 implies moderate vision impairment that needs further diagnostic assessment (26).

In one US study with 2,705 older adults, individuals with near vision impairment were more likely to be pre-frail and frail than those without visual loss (27). This result suggests an association between vision impairment, which promotes IC decline, and frailty (27). In this sense, some prospective studies have found that IC decline overlaps with frailty syndrome and can predict poor health outcomes in older adults (28–30).

Another UK prospective study with 493,737 middle-aged adults and older adults showed that individuals with glaucoma had a high prevalence of pre-fraility and frailty conditions (41.2 and 5%, respectively) (22). Equally, Wang et al. have found in a prospective China population-based study that this disease is associated with 10-year mortality (31).

The previously mentioned study by Hanlon et al. of middle-aged and older adults also revealed that patients with diabetes presented higher pre-fraility and frailty prevalence (54.8 and 13%, respectively) than glaucomatous ones (22). Besides, a systematic review has proved an association between diabetic retinopathy (DR, a major microvascular diabetes complication) and poor psychosocial functioning, affecting the quality of life of these patients (8, 32, 33). Likewise, a retrospective cohort study with 477 participants found that both frailty and diabetic microvascular complications can predict adverse clinical outcomes (e.g., emergency hospitalizations, institutionalization in a long-term care facility, falls, fractures, and death) in diabetic older adults (34).

Although the prevalence of pre-fraility/frailty in individuals with age-related macular degeneration (AMD) is yet unknown, Zhu et al. have suggested in a prospective study that late AMD is a biomarker of frailty syndrome (35). These authors argued that the poor survival observed in late AMD participants could be due to age- and frailty-related systemic comorbidities that coexist and share underlying molecular mechanisms with AMD (35). Moreover, several prospective studies have demonstrated that patients with AMD present a higher risk of falls and fear of falling, which leads to a decreased quality of life and disability (36–38). This fear of falling also has been observed in glaucomatous patients using the same validated questionnaire (the University of Illinois at Chicago Fear of Falling Questionnaire) (39). Some systematic reviews have also demonstrated an association between the fear of falling and poor quality of life with frailty (40, 41). Therefore, all these data seem to connect AMD and frailty.

A prospective study performed with age-related cataract patients found that they have poor survival rates, suggesting that cataracts, the most important cause of visual impairment and blindness, are also a biomarker of frailty (42). This study confirmed a previous cohort study that had shown
the association between age-related cataracts and some measures of frailty independent of visual acuity and systemic comorbidities (43).

Villani et al. have built an ocular surface frailty index (OSFI) and tested via a longitudinal study its capacity to identify frail-eye-ocular surfaces among patients who underwent cataract surgery (44). Consequently, these authors propose OSFI as a tool to predict patients with a high risk of post-surgical development of dry eye disease (DED) (44). This disease is also an age-related condition of the ocular surface that represents a growing problem with a substantial negative impact on the quality of life and global economy (45, 46).

To support this subsection, we searched in PubMed for the combination of the words: “frailty” and “eye” or one of the four age-related eye diseases leading causes of visual impairment/blindness: “cataracts”, “glaucoma”, “age-related macular degeneration”, and “diabetic retinopathy”. As we only aimed to summarize knowledge concerning this subsection’s topic, among all articles found, we selected those most recent and focused on our point of view.

Eye as a source of diagnostic biomarkers

The eye and especially the tear film have become, in recent years, the target for researchers of being an outstanding source of biomarkers for the diagnosis of both ocular and systemic diseases such as dry eye, Sjögren’s syndrome, keratoconus, cancer, and COVID-19 (47–52). The main reason for this is that tears are the most accessible corporal fluid, and collecting them is easier, faster, and less invasive than the collection methods of other fluids (53).

Tear film covers the external ocular surface and consists of an inner mucous/aqueous and an external lipid phase, presenting a great diversity of macromolecules that undergo measurable changes in pathological conditions (54–58). Among these conditions are age-related diseases, including eye diseases. So, tears have provided several potential biomarkers for cataracts, glaucoma, AMD, DR, Alzheimer’s, and Parkinson’s diseases (57, 59–63). Conversely, the presence of specific frailty biomarkers in tears is unknown.

Discussion

Age is a driving factor for frailty and age-related diseases, sharing underlying molecular mechanisms (64–66). According to the population aging and life expectancy prospects, these conditions, including eye-related ones, will be very prevalent (1, 2, 64). Age-related eye diseases are the world leading causes of visual impairment and blindness (6, 8). Hence, as the population ages, a growing number of visually impaired and blind people is expected, which will have an enormous humanistic and economic impact (8). These visual problems decrease the IC and quality of life of those affected by it and are associated with frailty syndrome (6–8, 27). Moreover, age-related eye diseases coexist with pre-frailty/frailty syndrome and are potential biomarkers of frailty and predictors of poor health outcomes (8, 22, 31, 34, 35, 42). These data reflect the crucial role of visual performance in achieving healthy aging (6). In this context, future studies should explore the validity of including new visual function-related tests in primary care for the integrated attention of older adults (6, 37, 39–41, 67). Indeed, some vision experts claim to perform the contrast sensitivity test to evaluate the fear of falling (a marker of poor quality of life, disability, and frailty) because it is a better predictor of this fear than the visual acuity test (37). Moreover, a recent cross-sectional study has found that poor contrast sensitivity is associated with frailty (68). Likewise, the older adults’ health programs could include questionnaires to measure fear of falling and quality of life previously validated in patients with age-related eye diseases (37, 39, 67).

The pivotal role of visual performance in achieving healthy aging also urges research in the diagnosis and treatment of age-related eye disorders fields to implement new global preventive and therapeutic strategies against those diseases (6).

Frailty syndrome, a geriatrician’s high-priority theme, has become an emerging target of gerontologists. They have found that this disorder that predisposes a person to age-related disease onsets is present in older and middle-aged adults and is associated with mortality, particularly in individuals with multi-morbidity (18, 21–23, 69). Given that a rapid intervention can reverse the condition, thus preventing its poor health outcome, gerontologists recommend screening frailty biomarkers in middle-aged adults (from the fourth decade of life onwards) (21–23, 69).

In this life period, presbyopia can also occur. This physiological process gradually reduces the ability of the eye to focus at different distances, impacting individuals without and with refractive errors (e.g., myopia, hyperopia, or astigmatism) who start to feel presbyopia symptoms from 40–50 years (12, 14). Because of these presbyopic symptoms, the entire population of middle-aged adults will visit eye care professionals seeking a solution. Probably, no other biomedical professionals attend to the whole population of middle-aged adults. This fact is remarkable because, as we have commented above, screening frailty biomarkers in middle-aged adults is critical for timely interventions to prevent age-related diseases and mortality.

Some data support the concept of age-related eye diseases as biomarkers of frailty phenotype and predictors of poor health outcomes (8, 22, 27, 31, 34, 35, 42, 67). Equally, data back the concept of the eye and its tear as a source of diagnostic biomarkers of ocular and systemic diseases, including age-related ones (57, 59–63). Thus, it would not be surprising that tears would contain frailty biomarkers. As any eye practitioner can easily
collect tears, screening for frailty biomarkers from tears of presbyopic subjects may represent an outstanding opportunity for early detection of pre-frailty and frailty states, allowing timely intervention and thus preventing poor clinical outcomes.

Molecular mechanisms of frailty could also arise at the eye level, as occur with aging and age-related diseases (65). Indeed, a systematic review has revealed recently that frailty mechanisms occur in oral tissues (70). In this sense, the prospective study of Villani et al. has suggested the existence of frailty underlying mechanisms at the ocular surface of individuals who undergo cataract surgery (44). Thus, a future screening of frailty biomarkers from tears of presbyopic subjects could be a simple method of studying possible ocular surface frailty mechanisms and how they could link to the processes that occur in the rest of the eye and body. The understanding of these mechanisms could provide new biomarkers, helping delay age-related diseases onsets, including eye ones.

In summary, this article aims to show that theoretically, it is possible to perform a simple and large-scale frailty screening of middle-aged adults’ tears, taking advantage of the unavoidable visit of presbyopic individuals to eye care professionals looking for a solution to their symptoms. The previous search for frailty biomarkers taken from tears of presbyopic people would allow this screening and thus timely interventions, delaying age-related diseases onsets and mortality.

We have confidence in the value of the tears of presbyopic people as an easy means to identify frail/pre-frail individuals, validate frailty biomarkers candidates, and study local frailty molecular mechanisms, which will provide new biomarkers.

Author contributions

AC, DM-C, and JR-A contributed to the research conception. AC, JR-A, and IM-A contributed to the literature review. AC and JR-A contributed to the manuscript writing. All authors contributed to the article and approved the submitted version.

Funding

This work has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 956274. IM-A holds a predoctoral fellowship from Universidad Complutense de Madrid and Banco Santander, Spain (CT63/19-CT64/19).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. United Nations, Department of Economic and Social Affairs, Population Division (2022). World Population Prospects 2022: Summary of Results. UN DESA/POP/2022/TR/NO. 3.
2. Akpek EK, Smith RA. Overview of age-related ocular conditions. Am J Manag Care. (2013) 19:567–75.
3. Burch JB, Augustine AD, Frieden LA, Hadley E, Howcroft TK, Johnson R, et al. Advances in geroscopy: impact on healthspan and chronic disease. J Gerontol A Biol Sci Med Sci. (2014) 69:S1–3. doi: 10.1093/gerona/giu041
4. United Nations. Department of Economic and Social Affairs, Population Division. World Population Prospects 2019: Highlights. St/Essa/Ser.A/423. (2019).
5. WHO. UN Decade of Healthy Ageing (2020-2030). (2020).
6. Burton MJ, Ramkie J, Marques AP, Bourne RRA, Congdon N, Jones I, et al. The Lancet Global Health Commission on Global Eye Health: Vision Beyond 2020. Lancet Glob Health. (2021) 9:e489–551. doi: 10.25259/IHOPEFO_15_2021
7. GBD 2019 Blindness and Vision Impairment Collaborators, VLEG. Trends in Prevalence of Blindness and Distance and near Vision Impairment over 30 Years: An Analysis for the Global Burden of Disease Study. Lancet Glob Health. (2021) 9:e130–e143. doi: 10.1016/S2214-109X(20)30425-3
8. GBD 2019 Blindness and Vision Impairment Collaborators, VLEG. Causes of Blindness and Vision Impairment in 2020 and Trends over 30 Years, and Prevalence of Avoidable Blindness in Relation to Vision 2020: The Right to Sight: An Analysis for the Global Burden of Disease Study. Lancet Glob Health. (2021) 9:e144–e60. doi: 10.1016/S2214-109X(20)30489-7
9. National Institute on Aging. Strategic Directions for Research 2020-2025. Available online at: https://www.nia.nih.gov/about/aging-strategic-directions-research (2020).
10. Martínez-Alberquilla I, Gasull X, Pérez-Luna P, Seco-Mera R, Ruiz-Alcocer I, Crooke A. Neutrophils and Neutrophil Extracellular Trap Components: Emerging Biomarkers and Therapeutic Targets for Age-Related Eye Diseases. Ageing Res Rev. (2022) 74:101553. doi: 10.1016/j.arr.2021.101553
11. Croft MA, McDonald JP, Katz A, Lin TL, Lütjen-Drecoll E, Kaufman PL. Extralenticular and Lenticular Aspects of Accommodation and Presbyopia in Human Versus Monkey Eyes. Invest Ophthalmol Vis Sci. (2013) 54:5035–48. doi: 10.1167/iovs.12-10846
12. Glasser A, Croft MA, Kaufman PL. Aging of the Human Crystalline Lens and Presbyopia. Int Ophthalmol Clin. (2001) 41:1–15. doi: 10.2981/IOCV.0004397.20010400.00003
13. Erdinest N, London N, Lavy I, Morad Y, Levinger N. Vision through Healthy Aging Eyes. Vision. (2021) 3:46. doi: 10.3390/vision3040046
14. Glaser A. Presbyopia. In: Darti D, editor. Encyclopedia of the Eye. Oxford: Academic Press (2010). p. 488–95. doi: 10.1016/B978-0-12-374203-2-00045-2
15. Goertz AD, Stewart WC, Burns WR, Stewart J, Nelson LA. Review of the impact of presbyopia on quality of life in the developing and developed world. Acta Ophthalmol. (2014) 92:497–500. doi: 10.1111/aos.12308
16. Luo BP, Brown GC, Luo SC, Brown MM. The quality of life associated with presbyopia. Am J Ophthalmol. (2008) 145:618–22. doi: 10.1016/j.ajo.2007.12.011
17. McDonnell PJ, Lee P, Spritzer K, Lindblad AS, Hays RD. Associations of presbyopia with vision-targeted health-related quality of life. Arch Ophthalmol. (2003) 121:1577–81. doi: 10.1001/archopht.121.11.1577
18. Falop T, Larbi A, Witurowski JM, McElhany J, Loeb M, Mintzitis A, et al. Aging, frailty and age-related diseases. Biogerontology. (2010) 11:547–63. doi: 10.1007/s10522-010-9287-2
19. O’Coaimuth R, Sergott D, O’Donovan MR, Molloy DW, Clegg A, Rockwood K, et al. Prevalence of frailty in 62 countries across the world: a systematic review and meta-analysis of population-level studies. Age Ageing. (2021) 50:96–104. doi: 10.1093/ageing/afaa219
20. Ofori-Asen 36. Szabo JM, Janssen PA, Khan K, Lord SR, Potter MJ. Neovascular and an overrisked factor for injuries among falls. Ophthalmol. (2010) 21:855–62. doi: 10.1016/j.ophtha.2009-1025-8
21. van Landingham SW, Massof RW, Chan E, Ferramond DS, Ramulay PY. Fear of falling in age-related macular degeneration. BMC Ophthalmol. (2014) 14:10. doi: 10.1186/1471-2415-14-10
22. Wood JM, Lacherez P, Black AA, Cole MH, Bown MY, Kerr GK. Risk of falls, injuries and falls, and other injuries resulting from visual impairment among older adults with age-related macular degeneration. Invest Ophthalmol Vis Sci. (2011) 52:5988–92. doi: 10.1167/iovs.10-6644
23. de Souza LF, Canever JB, Moreira BS, Gabinowicz AL, de Avelar NPC. Association between fear of falling and frailty in community-dwelling older adults: a systematic review and meta-analysis. Clin Interv Aging. (2021) 17:129–40. doi: 10.2147/CIA.S328423
24. Zhu Z, Wang L, Schertz J, He M. Age-related cataract and 10-year mortality: the liwan eye study. Acta Ophthalmol. (2020) 98:e328–e32. doi: 10.1111/aos.14258
25. Klein BE, Klein R, Knudtson MD. Frailty and 7-year mortality. Ophthalmol. (2006) 113:2239–12. doi: 10.1016/j.ophtha.2006.02.035
26. Villani E, Marello L, Bonsignore F, Lucentini S, Luccarello S, Schaci M, et al. The ocular surface frailty index as a predictor of ocular surface symptom onset after cataract surgery. Ophthalmol. (2020) 127:866–73. doi: 10.1016/j.ophtha.2019.12.012
27. McDonald M, Patil DA, Keith MS, Snedcor SJ. Economic and humanistic burden of dry eye disease in europe, north america, and asia: a systematic literature review. Ocul Surf. (2016) 14:144–67. doi: 10.1016/j.jtos.2015.11.002
28. Uchino M, Schaubenberg D. Dry eye disease: impact on quality of life and vision. Curr Opin Ophthalmol. (2013) 1:51–7. doi: 10.1097/ium.0b013e32835f00-1
29. Arora R, Gosw R, Kumar S, Chhabra M, Saxena S, Manchanda V, et al. Evaluation of SARS-CoV-2 tears in patients with moderate to severe Covid-19. Ophthalmol. (2021) 128:494–503. doi: 10.1016/j.ophtha.2020.08.029
30. Asiedu K, Markouz L, Bonini S, Brown AL, Dogru M, Kwait N, et al. Tear film and ocular surface neuropeptides: characteristics, synthesis, sampling and implications for ocular surface and systemic diseases. Exp Eye Res. (2022) 218:108973. doi: 10.1016/j.eyexres.2022.108973
31. Hagan S, Martin E, Enríquez-de-Salamanca A. Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine. Exp Eye Res. (2016) 5:7:15. doi: 10.1016/j.exer.2015.11.002
32. Nandi SK, Singh D, Upadhyay J, Gupta N, Dhinan N, Mittal SK, et al. Identification of tear-based protein and non-protein biomarkers: its application in diagnosis of human diseases using biosensors. Int J Biol Macromol. (2021) 193:838-46. doi: 10.1016/j.ijbiomac.2021.10.198
33. von Thun Und Hohenstein-Blaul N, Funke S, Gris FH. Tears as a source of biomarkers for ocular and systemic diseases. Exp Eye Res. (2015) 117:126–37. doi: 10.1016/j.exer.2015.07.015
34. Zhan X, Li J, Guo Y, Gohunmishica O. Mass spectrometry analysis of human tear fluid biomarkers specific for ocular and systemic diseases in the context of 3p medicine. EMJ (2016) 1:15. doi: 10.1186/s41305-013-0009-7
35. Barnarda M, Ashpay S. Tear analysis as the next routine body fluid test. Eye (Lond). (2020) 34:17031–3. doi: 10.1038/s41433-020-0930-0
36. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. Tlos dews is pathophysiology report. Ocul Surf. (2017) 15:438–510. doi: 10.1016/j.jtos.2017.05.011
37. Cicalini I, Rossi C, Pieragostino D, Agnifili L, Mastropasqua L, di Iosa M, et al. Integrated lipidomics and metabolomics analysis of tears in multiple sclerosis: an insight into diagnostic potential of lacrimal fluid. Int J Mol Sci. (2020) 21:12655. doi: 10.3390/ijms20061265
38. Gijs M, Ramakers I, Visser PJ, Verhey FR, van de Waarden MPH, Schalkwyk CG, et al. Association of tear fluid amyloids and tau levels in older patients with severity and neurodegeneration. Sci Rep. (2021) 11:26275. doi: 10.1038/s41598-021-10993-x
39. Kenny A, Jimnez-Mateos EM, Zea-Sevilla MA, Rabanco A, Gil-Manzanares P, Prehn JHM, et al. Proteins and micromas are differentially...
expressed in tear fluid from patients with Alzheimer's disease. Sci Rep. (2019) 9:15437. doi: 10.1038/s41598-019-51837-y

58. Nguyen-Khuong T, Everest-Dass AV, Kautto L, Zhao Z, Willcox MD, Packer NH. Glycomic characterization of basal tears and changes with diabetes and diabetic retinopathy. Glycobiology. (2015) 25:269–83. doi: 10.1093/glycob/cwu108

59. Acera A, Gómez-Esteban JC, Murueta-Goyena A, Galdos M, Azkargorta M, Elortza F, et al. Potential tear biomarkers for the diagnosis of parkinson’s disease-a pilot study. Proteomes. (2022) 10:4. doi: 10.3390/proteomes10010004

60. Costagliola C, Romano V, De Tolla M, Aceto F, dell’Omo R, Romano MR, et al. Tnf-Alpha Levels in Tears: A Novel Biomarker to Assess the Degree of Diabetic Retinopathy. Mediators Inflamm. (2013) 2013:629529. doi: 10.1155/2013/629529

61. Engelbrecht C, Sardinha LR, Rizoiu LV. Cytokine and chemokine concentration in the tear of patients with age-related cataract. Curr Eye Res. (2020) 45:1101–6. doi: 10.1080/02713683.2020.1715445

62. Gupta D, Wen J, Huebner JL, Stinnett S, Kraus VB, Tseng HC, et al. Cytokine biomarkers in tear film for primary open-angle glaucoma. Clin Ophthalmol. (2017) 11:411–6. doi: 10.2147/OPTH.S125364

63. Winiarczyk M, Winiarczyk D, Michalak K, Kaarmiranta K, Adaszek Ł, Winiarczyk S, et al. Dysregulated tear film proteins in macular edema due to the neovascular age-related macular degeneration are involved in the regulation of protein clearance, inflammation, and neovascularization. J Clin Med. (2021) 10:60. doi: 10.3390/jcm10140360

64. Franceschi C, Garagnani P, Morsiani C, Conte M, Santoro A, Grignolio A, et al. The continuum of aging and age-related diseases: common mechanisms but different rates. Front Med (Lausanne). (2018) 5:61. doi: 10.3389/fmed.2018.00061

65. Crooke A, Huete-Toral F, Colligris B, Pintor J. The role and therapeutic potential of melatonin in age-related ocular diseases. J Pineal Res. (2017) 65:12430. doi: 10.1111/jpe.12430

66. Johnson SC, Dong X, Vij J, Suh Y. Genetic evidence for common pathways in human age-related diseases. Aging Cell. (2015) 14:809–17. doi: 10.1111/acel.12362

67. Assi L, Chamseddine F, Ibrahim P, Sabbagh H, Rosman L, Congdon N, et al. A global assessment of eye health and quality of life: a systematic review of systematic reviews. JAMA Ophthalmol. (2021) 139:526–41. doi: 10.1001/jamaophthalmol.2021.0146

68. Amir NN, Kamaruzzaman SB, Effendi-Tenang I, Jamahuddin M, Tan MP, Ramli N, et al. Contrast sensitivity is associated with frailty. Eur Geriatr Med. (2021) 12:313–9. doi: 10.1007/s41999-021-00450-2

69. Sacha J, Sacha M, Sobosy J, Borysiuk Z, Feusette P. Is it time to begin a public campaign concerning frailty and pre-frailty? A review article. Front Physiol. (2017) 8:484. doi: 10.3389/fphys.2017.00484

70. Dibello V, Zupo R, Sardone R, Lozupone M, Castellana F, Dibello A, et al. Oral frailty and its determinants in older age: a systematic review. Lancet Healthy Longevity. (2021) 2:e507–e20. doi: 10.1016/S2666-7568(21)00143-4